Submit Manuscript  

Article Details

Perspectives on Bioanalytical Mass Spectrometry and Automation in Drug Discovery

[ Vol. 9 , Issue. 9 ]


John S. Janiszewski, Theodore E. Liston and Mark J. Cole   Pages 986 - 994 ( 9 )


The use of high speed synthesis technologies has resulted in a steady increase in the number of new chemical entities active in the drug discovery research stream. Large organizations can have thousands of chemical entities in various stages of testing and evaluation across numerous projects on a weekly basis. Qualitative and quantitative measurements made using LC/MS are integrated throughout this process from early stage lead generation through candidate nomination. Nearly all analytical processes and procedures in modern research organizations are automated to some degree. This includes both hardware and software automation. In this review we discuss bioanalytical mass spectrometry and automation as components of the analytical chemistry infrastructure in pharma. Analytical chemists are presented as members of distinct groups with similar skillsets that build automated systems, manage test compounds, assays and reagents, and deliver data to project teams. The ADME-screening process in drug discovery is used as a model to highlight the relationships between analytical tasks in drug discovery. Emerging software and process automation tools are described that can potentially address gaps and link analytical chemistry related tasks. The role of analytical chemists and groups in modern ‘industrialized’ drug discovery is also discussed.


ADME, high-throughput, LC/MS/MS, automation, drug discovery, software


Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.

Read Full-Text article